본문 바로가기
KERD
논문KCI 등재

Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management

Sara Battistella|Francesca D’Arcangelo|Marco Grasso|Alberto Zanetto|Martina Gambato|Giacomo Germani|Marco Senzolo|Francesco Paolo Russo|Patrizia Burra
대한간학회 (The korean Association for the Study of the Liver)|2023.02|Clinical and Molecular Hepatology|제29권 제1호|pp. 286-301

2

조회

0

다운로드

1

인용

0

참고문헌

키워드

Metabolic syndromeLiver transplantationCardiovascular riskNAFLDNASH

초록

Non-alcoholic fatty liver disease (NAFLD) is currently the fastest growing indication to liver transplantation (LT) in Western Countries, both for end stage liver disease and hepatocellular carcinoma. NAFLD/non-alcoholic steatohepatitis (NASH) is often expression of a systemic metabolic syndrome; therefore, NAFLD/NASH patients require a multidisciplinary approach for a proper pre-surgical evaluation, which is important to achieve a post-transplant outcome comparable to that of other indications to LT. NAFLD/NASH patients are also at higher risk of post-transplant cardiovascular events, diabetes, dyslipidemia, obesity, renal impairment and recurrent NASH. Lifestyle modifications, included diet and physical activity, are key to improve survival and quality of life after transplantation. A tailored immunosuppressive regimen may be proposed in selected patients. Development of new drugs for the treatment of recurrent NASH is awaited.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is currently the fastest growing indication to liver transplantation (LT) in Western Countries, both for end stage liver disease and hepatocellular carcinoma. NAFLD/non-alcoholic steatohepatitis (NASH) is often expression of a systemic metabolic syndrome; therefore, NAFLD/NASH patients require a multidisciplinary approach for a proper pre-surgical evaluation, which is important to achieve a post-transplant outcome comparable to that of other indications to LT. NAFLD/NASH patients are also at higher risk of post-transplant cardiovascular events, diabetes, dyslipidemia, obesity, renal impairment and recurrent NASH. Lifestyle modifications, included diet and physical activity, are key to improve survival and quality of life after transplantation. A tailored immunosuppressive regimen may be proposed in selected patients. Development of new drugs for the treatment of recurrent NASH is awaited.

참고문헌 (119)

  1. Cotter TG, "Nonalcoholic steatohepatitis after liver transplantation", Liver Transpl, 26, pp.141~159 (2020)
  2. Adam R, "2018 Annual Report of the European Liver Transplant Registry (ELTR) - 50-year evolution of liver transplantation", Transpl Int, 31, pp.1293~1317 (2018)
  3. Eslam M, "A new definition for metabolic dysfunction-associated fatty liver disease : An international expert consensus statement", J Hepatol, 73, pp.202~209 (2020)
  4. Eslam M, "MAFLD : A consensus-driven proposed nomenclature for metabolic associated fatty liver disease", Gastroenterology, 158, pp.1999~2014 (2020)
  5. Boyle M, "The bidirectional impacts of alcohol consumption and the metabolic syndrome : Cofactors for progressive fatty liver disease", J Hepatol, 68, pp.251~267 (2018)
  6. Kim D, "Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States", J Hepatol, 75, pp.1284~1291 (2021)
  7. Younossi ZM, "The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe", Hepatology, 64, pp.1577~1586 (2016)
  8. Jaejun Lee, "Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population- based cross-sectional study", Clinical and Molecular Hepatology, 28(2), pp.196~206 (2022), 대한간학회[DOI]
  9. Estes C, "Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease", Hepatology, 67, pp.123~133 (2018)
  10. Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : Practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 67, pp.328~357 (2018)
  11. Haldar D, "Outcomes of liver transplantation for nonalcoholic steatohepatitis: A European Liver Transplant Registry study", J Hepatol, 71, pp.313~322 (2019)
  12. Margini C, "The story of HCC in NAFLD : from epidemiology, across pathogenesis, to prevention and treatment", Liver Int, 36, pp.317~324 (2016)
  13. Karagozian R, "Obesity-associated mechanisms of hepatocarcinogenesis", Metabolism, 63, pp.607~617 (2014)
  14. Piscaglia F, "Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study", Hepatology, 63, pp.827~838 (2016)
  15. Ertle J, "Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis", Int J Cancer, 128, pp.2436~2443 (2011)
  16. Yasui K, "Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma", Clin Gastroenterol Hepatol, 9, pp.428~433 (2011)[DOI]
  17. Moreau R, "Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis", Gastroenterology, 144, pp.1426~1437 (2013)
  18. Zanetto A, "Severity of systemic inflammation is the main predictor of ACLF and bleeding in individuals with acutely decompensated cirrhosis", J Hepatol (2022)[DOI]
  19. Axley P, "NASH is the most rapidly growing etiology for acute-onchronic liver failure-related hospitalization and disease burden in the United States : a population-based study", Liver Transpl, 25, pp.695~705 (2019)
  20. Mahmud N, "Incidence and mortality of acute-on-chronic liver failure using two definitions in patients with compensated cirrhosis", Hepatology, 69, pp.2150~2163 (2019)
  21. Sundaram V, "Factors associated with survival of patients with severe acuteon-chronic liver failure before and after liver transplantation", Gastroenterology, 156, pp.1381~1391 (2019)
  22. Thuluvath PJ, "Liver transplantation in patients with multiple organ failures : Feasibility and outcomes", J Hepatol, 69, pp.1047~1056 (2018)
  23. European Association for the Study of the Liver, "EASL Clinical Practice Guidelines : Liver transplantation", J Hepatol, 64, pp.433~485 (2016)
  24. Burra P, "NAFLD and liver transplantation : Disease burden, current management and future challenges", JHEP Rep, 2, pp.100192~ (2020)
  25. Skaro AI, "The impact of coronary artery disease on outcomes after liver transplantation", J Cardiovasc Med(Hagerstown), 17, pp.875~885 (2016)
  26. Vanwagner LB, "Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events", Hepatology, 56, pp.1741~1750 (2012)
  27. Martin P, "Evaluation for liver transplantation in adults : 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation", Hepatology, 59, pp.1144~1165 (2014)
  28. Cheng XS, "Emerging evidence on coronary heart disease screening in kidney and liver transplantation candidates: A scientific statement from the American Heart Association: Endorsed by the American Society of Transplantation", Circulation, 146(21), pp.e299~e324 (2022)
  29. Lentine KL, "Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation: endorsed by the American Society of Transplant Surgeons, American Society of Transplantation, and National Kidney Foundation", Circulation, 126, pp.617~663 (2012)
  30. Główczyńska R, "The pre-transplant profile of cardiovascular risk factors and its impact on longterm mortality after liver transplantation", Ann Transplant, 23, pp.591~597 (2018)
  31. VanWagner LB, "A point-based prediction model for cardiovascular risk in orthotopic liver transplantation : The CAR-OLT score", Hepatology, 66, pp.1968~1979 (2017)
  32. Koshy AN, "Effect of QT interval prolongation on cardiac arrest following liver transplantation and derivation of a risk index", Am J Transplant, 21, pp.593~603 (2021)
  33. Rachwan RJ, "CAD-LT score effectively predicts risk of significant coronary artery disease in liver transplant candidates", J Hepatol, 75, pp.142~149 (2021)
  34. Fussner LA, "Cardiovascular disease after liver transplantation : when, what, and who is at risk", Liver Transpl, 21, pp.889~896 (2015)
  35. Watt KD, "Serum adipokine and inflammatory markers before and after liver transplantation in recipients with major cardiovascular events", Liver Transpl, 20, pp.791~797 (2014)
  36. West BH, "Significance of coronary artery calcium found on nonelectrocardiogram-gated computed tomography during preoperative evaluation for liver transplant", Am J Cardiol, 124, pp.278~284 (2019)
  37. Zorzi A, "Coronary artery calcium on standard chest computed tomography predicts cardiovascular events after liver transplantation", Int J Cardiol, 339, pp.219~224 (2021)
  38. Kristensen SD, "2014 ESC", ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery:cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA)., 2014, pp.35, 2383~2431
  39. Patel SS, "Coronary artery disease in decompensated patients undergoing liver transplantation evaluation", Liver Transpl, 24, pp.333~342 (2018)
  40. Patel SS, "The impact of coronary artery disease and statins on survival after liver transplantation", Liver Transpl, 25, pp.1514~1523 (2019)
  41. Löffler AI, "Coronary computed tomography angiography demonstrates a high burden of coronary artery disease despite low-risk nuclear studies in pre-liver transplant evaluation", Liver Transpl, 26, pp.1398~1408 (2020)
  42. Min JK, "Diagnostic accuracy of fractional flow reserve from anatomic CT angiography", JAMA, 308, pp.1237~1245 (2012)
  43. Hara N, "Sarcopenia and sarcopenic obesity are prognostic factors for overall survival in patients with cirrhosis", Intern Med, 55, pp.863~870 (2016)
  44. Itoh S, "Effect of sarcopenic obesity on outcomes of living-donor liver transplantation for hepatocellular carcinoma", Anticancer Res, 36, pp.3029~3034 (2016)
  45. Nagai S, "Disease-specific waitlist outcomes in liver transplantation-a retrospective study", Transpl Int, 34, pp.499~513 (2021)
  46. Thuluvath PJ, "Waiting list mortality and transplant rates for NASH cirrhosis when compared with cryptogenic, alcoholic, or AIH cirrhosis", Transplantation, 103, pp.113~121 (2019)
  47. Younossi Z, "Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates", Clin Gastroenterol Hepatol, 17, pp.748~755 (2019)
  48. Young K, "Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma", Liver Transpl, 22, pp.1356~1366 (2016)
  49. Reddy SK, "Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease", Hepatology, 55, pp.1809~1819 (2012)
  50. Spengler EK, "Liver transplantation in the obese cirrhotic patient", Transplantation, 101, pp.2288~2296 (2017)
  51. Dare AJ, "Additive effect of pretransplant obesity, diabetes, and cardiovascular risk factors on outcomes after liver transplantation", Liver Transpl, 20, pp.281~290 (2014)
  52. Wolter S, "Influence of liver disease on perioperative outcome after bariatric surgery in a Northern German cohort", Obes Surg, 27, pp.90~95 (2017)
  53. Wigfield CH, "Is extreme obesity a risk factor for cardiac surgery? An analysis of patients with a BMI > or = 40", Eur J Cardiothorac Surg, 29, pp.434~440 (2006)
  54. van den Berg EH, "Liver transplantation for NASH cirrhosis is not performed at the expense of major post-operative morbidity", Dig Liver Dis, 50, pp.68~75 (2018)
  55. Stepanova M, "Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population", Clin Gastroenterol Hepatol, 10, pp.646~650 (2012)
  56. Sastre L, "Results of a multidisciplinary strategy to improve the management of cardiovascular risk factors after liver transplantation", Liver Transpl, 28, pp.1332~1344 (2022)
  57. John PR, "Outcome of patients with new-onset diabetes mellitus after liver transplantation compared with those without diabetes mellitus", Liver Transpl, 8, pp.708~713 (2002)
  58. Saliba F, "Risk factors for newonset diabetes mellitus following liver transplantation and impact of hepatitis C infection: an observational multicenter study", Liver Transpl, 13, pp.136~144 (2007)
  59. Kuo HT, "Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network", United Network for Organ Sharing database, 2010, pp.89, 1134~1140
  60. Ramos-Prol A, "Outcomes in patients with diabetes 10 years after liver transplantation", J Diabetes, 9, pp.1033~1039 (2017)
  61. Bhat V, "New-onset diabetes and preexisting diabetes are associated with comparable reduction in long-term survival after liver transplant : a machine learning approach", Mayo Clin Proc, 93, pp.1794~1802 (2018)
  62. Peláez-Jaramillo MJ, "Post-liver transplantation diabetes mellitus : a review of relevance and approach to treatment", Diabetes Ther, 9, pp.521~543 (2018)
  63. Lucey MR, "Long-term management of the successful adult liver transplant : 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation", Liver Transpl, 19, pp.3~26 (2013)
  64. Giugliano D, "GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes : an updated meta-analysis of eight CVOTs", Cardiovasc Diabetol, 20(1), pp.189~ (2021)
  65. Pereira MJ, "Emerging role of SGLT-2 inhibitors for the treatment of obesity", Drugs, 79, pp.219~230 (2019)
  66. Ling Q, "Major influence of renal function on hyperlipidemia after living donor liver transplantation", World J Gastroenterol, 18, pp.7033~7039 (2012)
  67. Azhie A, "Metabolic complications in liver transplantation recipients : how we can optimize long-term survival", Liver Transpl, 27, pp.1468~1478 (2021)
  68. Almutairi F, "Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia", Liver Transpl, 15, pp.504~508 (2009)
  69. Lee S, "Omega-3 fatty acids and liver disease", Hepatology, 45, pp.841~845 (2007)
  70. 강성희, "KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 27(3), pp.363~401 (2021), 대한간학회
  71. Wijarnpreecha Karn, "Evaluation and Management of Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease", Clinical and Molecular Hepatology, 27(2), pp.221~235 (2021), 대한간학회[DOI]
  72. Diwan TS, "Liver transplantation and bariatric surgery : timing and outcomes", Liver Transpl, 24, pp.1280~1287 (2018)
  73. Zamora-Valdes D, "Long-term outcomes of patients undergoing simultaneous liver transplantation and sleeve gastrectomy", Hepatology, 68, pp.485~495 (2018)
  74. Lin MY, "Safety and feasibility of sleeve gastrectomy in morbidly obese patients following liver transplantation", Surg Endosc, 27, pp.81~85 (2013)
  75. Osseis M, "Sleeve gastrectomy after liver transplantation : feasibility and outcomes", Obes Surg, 28, pp.242~248 (2018)
  76. Salomone F, "Endoscopic bariatric and metabolic therapies for non-alcoholic fatty liver disease : Evidence and perspectives", Liver Int, 40, pp.1262~1268 (2020)
  77. Izzy M, "Redefining cirrhotic cardiomyopathy for the modern era", Hepatology, 71, pp.334~345 (2020)
  78. Narayanan P, "Recurrent or de novo allograft steatosis and longterm outcomes after liver transplantation", Transplantation, 103, pp.e14~e21 (2019)
  79. Yong JN, "Outcomes of nonalcoholic steatohepatitis after liver transplantation : an updated meta-analysis and systematic review", Clin Gastroenterol Hepatol, 21, pp.45~54 (2023)
  80. Assmann G, "Assessing risk of myocardial infarction and stroke : new data from the Prospective Cardiovascular Münster(PROCAM)study", Eur J Clin Invest, 37, pp.925~932 (2007)
  81. Conroy RM, "Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project", Eur Heart J, 24, pp.987~1003 (2003)
  82. Writing Committee, "2021 Update to the 2017ACC expert consensus decision pathway for optimization of heart failure treatment : answers to 10 pivotal issues about heart failure with reduced ejection fraction : a report of the American College of Cardiology Solution Set Oversight Committee", J Am Coll Cardiol, 77, pp.772~810 (2021)
  83. Neal DA, "Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight", Liver Transpl, 7, pp.533~539 (2001)
  84. Bhati C, "Long-term outcomes in patients undergoing liver transplantation for nonalcoholic steatohepatitis-related cirrhosis", Transplantation, 101, pp.1867~1874 (2017)
  85. Laish I, "Metabolic syndrome in liver transplant recipients : prevalence, risk factors, and association with cardiovascular events", Liver Transpl, 17, pp.15~22 (2011)
  86. Dureja P, "NAFLD recurrence in liver transplant recipients", Transplantation, 91, pp.684~689 (2011)
  87. Saeed N, "Incidence and risks for nonalcoholic fatty liver disease and steatohepatitis post-liver transplant : systematic review and meta-analysis", Transplantation, 103, pp.e345~e354 (2019)
  88. Germani G, "Management of recurrent and de novo NAFLD", NASH after liver transplantation, 2019, pp.103, 57~67
  89. Neuschwander-Tetri BA, "Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT):a multicentre, randomised, placebo-controlled trial", Lancet, 385, pp.956~965 (2015)
  90. Younossi ZM, "Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial", Lancet, 394, pp.2184~2196 (2019)
  91. Gastaldelli A, "PPAR-γ-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH", Liver Int, 41, pp.2659~2670 (2021)
  92. Newsome PN, "A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis", N Engl J Med, 384, pp.1113~1124 (2021)
  93. Ratziu V, "Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial", Nat Med, 27, pp.1825~1835 (2021)
  94. Assy N, "Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis", Gut, 56, pp.443~444 (2007)
  95. Kwong A, "OPTN", SRTR 2018 annual data report : liver, 2020, pp.20 Suppl(s1), 193~299
  96. Ojo AO, "Chronic renal failure after transplantation of a nonrenal organ", N Engl J Med, 349, pp.931~940 (2003)
  97. Rubín A, "Long-term outcome of ‘long-term liver transplant survivors’", Transpl Int, 26, pp.740~750 (2013)
  98. D’Avola D, "Cardiovascular morbidity and mortality after liver transplantation : The protective role of mycophenolate mofetil", Liver Transpl, 23, pp.498~509 (2017)
  99. Neuberger JM, "Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the ‘ReSpECT’ study", Am J Transplant, 9, pp.327~336 (2009)
  100. Kezic A, "mTOR inhibitor therapy and metabolic consequences : where do we stand?", Oxid Med Cell Longev, 2018, pp.2640342~ (2018)
  101. Incheon Kang, "Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma", Clinical and Molecular Hepatology, 27(4), pp.589~602 (2021), 대한간학회[DOI]
  102. Bhanji RA, "Differing impact of sarcopenia and frailty in nonalcoholic steatohepatitis and alcoholic liver disease", Liver Transpl, 25, pp.14~24 (2019)
  103. Bhanji RA, "Sarcopenia in hiding : The risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis", Hepatology, 66, pp.2055~2065 (2017)
  104. Cai C, "Relationship between relative skeletal muscle mass and nonalcoholic fatty liver disease : a systematic review and meta-analysis", Hepatol Int, 14, pp.115~126 (2020)
  105. Ooi PH, "Sarcopenia in chronic liver disease : impact on outcomes", Liver Transpl, 25, pp.1422~1438 (2019)
  106. Hong HC, "Relationship between sarcopenia and nonalcoholic fatty liver disease : the Korean Sarcopenic Obesity Study", Hepatology, 59, pp.1772~1778 (2014)
  107. Tsien C, "Post-liver transplantation sarcopenia in cirrhosis : a prospective evaluation", J Gastroenterol Hepatol, 29, pp.1250~1257 (2014)
  108. Dasarathy S, "Posttransplant sarcopenia : an underrecognized early consequence of liver transplantation", Dig Dis Sci, 58, pp.3103~3111 (2013)
  109. Dickinson JM, "Mammalian target of rapamycin complex 1 activation is required for the stimulation of human skeletal muscle protein synthesis by essential amino acids", J Nutr, 141, pp.856~862 (2011)
  110. Pravisani R, "Chronological changes in skeletal muscle mass following living-donor liver transplantation : An analysis of the predictive factors for long-term post-transplant low muscularity", Clin Transplant, 33, pp.e13495~ (2019)
  111. Jeon JY, "Newly developed sarcopenia as a prognostic factor for survival in patients who underwent liver transplantation", PLoS One, 10, pp.e0143966~ (2015)
  112. Bhanji RA, "The evolution and impact of sarcopenia pre-and post-liver transplantation", Aliment Pharmacol Ther, 49, pp.807~813 (2019)
  113. Carias S, "Nonalcoholic steatohepatitis is strongly associated with sarcopenic obesity in patients with cirrhosis undergoing liver transplant evaluation", J Gastroenterol Hepatol, 31, pp.628~633 (2016)
  114. Baumgartner RN, "Body composition in healthy aging", Ann N Y Acad Sci, 904, pp.437~448 (2000)
  115. Eslamparast T, "Sarcopenic obesity in cirrhosis-The confluence of 2 prognostic titans", Liver Int, 38, pp.1706~1717 (2018)
  116. Hegyi PJ, "Pre-transplant sarcopenic obesity worsens the survival after liver transplantation: a meta-analysis and a systematic review", Front Med(Lausanne), 7, pp.599434~ (2020)
  117. Minich A, "Predictors of patient survival following liver transplant in non-alcoholic steatohepatitis : A systematic review and meta-analysis", EClinicalMedicine, 50, pp.101534~ (2022)
  118. Sadler EM, "Liver transplantation for NASH-related hepatocellular carcinoma versus non-NASH etiologies of hepatocellular carcinoma", Transplantation, 102, pp.640~647 (2018)
  119. Younossi Z, "The burden of non-alcoholic steatohepatitis : A systematic review of health-related quality of life and patient-reported outcomes", JHEP Rep, 4, pp.100525~ (2022)

관련 논문AI추천

How to optimize the outcome of liver transplantation for non-alcoholic fatty liver diseaseByeong Geun Song, Dong Hyun Sinn대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제2호Bariatric surgery for non-alcoholic fatty liver disease: Indications and post-operative managementAnja Geerts, Sander Lefere대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제1호Liver TransplantationDeok-Bog Moon, Sung-Gyu Lee거트앤리버 소화기연관학회협의회 · Gut and Liver2009 · 제3권 제3호Recent research trends and updates on nonalcoholic fatty liver disease김원, 김상균, 이진우, 조용균, Jeong-Ju Yoo, Jong Eun Yeon, Joo Hyun Sohn, KASL-KNSG, Moon Young Kim, Sang Hoon Park대한간학회 · Clinical and Molecular Hepatology2019 · 제25권 제1호Alcohol use disorder and liver transplant: new perspectives and critical issuesFabio Caputo, Fabio Marra, Francesco Vizzutti, Lucia Golfieri, Silvana Grandi, Silvia Aspite, Stefano Gitto, Valentino Patussi대한내과학회 · The Korean Journal of Internal Medicine2020 · 제35권 제4호Expanding Indications for Liver Transplant: Tumor and Patient FactorsChok Kenneth Siu-Ho, Chu Kevin Ka-Wan, Wong Kelly Hiu-Ching거트앤리버 소화기연관학회협의회 · Gut and Liver2021 · 제15권 제1호

이 간행물의 다른 논문 (46건)

Subclinical versus advanced forms of alcohol-related liver disease: Need for early detectionLuma Melo, David Martí-Aguado, Ramón Bataller, Concepción Gómez-Medinapp. 1-15PrefaceYoon Jun Kimpp. 2-2PrefaceSeung Up Kimpp. 3-3Non-alcoholic fatty liver disease: Definition and subtypesSeul Ki Han, 김문영, 백순구pp. 5-16Management of refractory ascitesFlorence Wongpp. 16-32
원문 보기